CMR Surgical has raised US$600m (£425m) in Series D financing, with the funds being used to not only increase commercialisation of its Versius system but also drive the development of its next generation of surgical robots.
The UK-based company works with surgeons and hospitals to provide a tool to make robotic keyhole surgery universally accessible and affordable. CMR said Versius’ size, portability and versatility have made it very popular with hospitals and surgeons around the world.
As part of CMR’s ongoing international expansion, Versius has launched in multiple geographies worldwide including across Europe, Australia, India and the Middle East. Global demand for CMR’s surgical robot continues to grow with significant further momentum anticipated.
Per Vegard Nerseth, chief executive officer of CMR, said: “This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals.
“This major injection of capital that now values us at US$3bn not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion.”
This latest funding round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group. Yanni Pipilis, managing partner for SoftBank Investment Advisers, added: “Demand for minimally invasive robotic surgery is growing rapidly among surgeons and patients yet high costs have historically hindered adoption.
“CMR Surgical is transforming surgical robotics to convert under-penetrated open & laparoscopic procedures in new international markets where robotic surgeries are less prevalent such as India, the Middle East and Latin America. We look forward to working with CMR in its mission to make robotic keyhole surgery available to everyone.”
